Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
334,705,968
-
Total 13F shares
-
1,121,093
-
Share change
-
+296,369
-
Total reported value
-
$8,466,233
-
Price per share
-
$7.49
-
Number of holders
-
39
-
Value change
-
+$2,229,104
-
Number of buys
-
25
-
Number of sells
-
13
Institutional Holders of Telix Pharmaceuticals Ltd - Ordinary Shares (TLX) as of Q4 2025
As of 31 Dec 2025,
Telix Pharmaceuticals Ltd - Ordinary Shares (TLX) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,121,093 shares.
The largest 10 holders included
PORTLAND INVESTMENT COUNSEL INC., LAZARD ASSET MANAGEMENT LLC, FMR LLC, JPMORGAN CHASE & CO, MARSHALL WACE, LLP, Private Advisor Group, LLC, JANE STREET GROUP, LLC, Quadrature Capital Ltd, Mariner, LLC, and Vident Advisory, LLC.
This page lists
39
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.